<DOC>
	<DOC>NCT00218413</DOC>
	<brief_summary>Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.</brief_summary>
	<brief_title>Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals</brief_title>
	<detailed_description>Tobacco use is the single leading preventable cause of death in the United States. Nicotine is an alkaloid that is derived from the tobacco plant responsible for the psychoactive and addictive effects of smoking. Immunotherapy may be useful in preventing and treating nicotine dependent individuals. NicVAX is a nicotine vaccine, a type of immunotherapy that may be effective in smoking cessation and preventing relapse to nicotine. The purpose of this study is to evaluate the safety and efficacy of various dosing levels and dosing frequencies of NicVAX in treating nicotine dependent individuals.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Current smoker Good general health, including mental health Alveolar carbon monoxide level greater than or equal to 10 ppm Prior exposure to NicVAX Known allergy to any of the components of NicVAX Use of any smoking cessation aide Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Addiction</keyword>
</DOC>